2019 American Transplant Congress
Tacrolimus Activated BMP Signaling Acts in Synergy with Stress-Activated FOXO1 to Induce Loss of Beta-Cell Function and Identity
*Purpose: Tacrolimus, the most widely used immunosuppressive drug, is known to be highly diabetogenic. It is thought to trigger β-cell death through inhibition of the…2019 American Transplant Congress
Excellent Outcome in African-American (AA), Type 1 and Type 2 Diabetic Recipients after Simultaneous Pancreas and Kidney Transplantation (SPK)
SUNY Downstate Medical Center, Brooklyn, NY
*Purpose: African-American recipients (AA) are considered a high risk group for organ transplantation. As outcomes after pancreas transplantation have significantly improved, the number of transplants…2019 American Transplant Congress
Thymoglobulin Efficacy: The Role of Dosing on Viral Infection and Rejection in Pancreas Transplantation
Transplant Surgery, University of Minnesota Medical Center, Minneapolis, MN
*Purpose: While T-cell depletion therapy is standard practice for induction in pancreas transplantation, little data exists to help determine dosing and its impact on efficacy…2019 American Transplant Congress
Use of Belatacept in Pancreas Transplantation
Kidney/Pancreas Transplantation, ITAC - Nephrology, Buenos Aires, Argentina
*Purpose: To review our experience with Belatacept in pancreas transplantation*Methods: Retrospective review including all patients receiving Belatacept after pancreas transplantation. Main objective is to review…2019 American Transplant Congress
microRNA-375 Provides an Objective Measure of Pancreas Quality in Organ Donors
*Purpose: Donor pancreatic beta cells are at high risk from apoptosis. Objective methods for assessing the quality of donor pancreases for transplantation are limited. We…2019 American Transplant Congress
The Protective Effects of siRNA Conjugated Nanoparticles in Pancreatic Islet Cells after Transplant
Columbia Center for Translational Immunology, Columbia University, New York, NY
*Purpose: To utilize a novel technology involving siRNA conjugated iron oxide nanoparticles to protect against ischemic damage to islet cells before transplant, therefore minimizing the…2019 American Transplant Congress
Policy Changes in Facilitated Pancreas Allocation Support Pancreas Utilization
*Purpose: In an effort to address the decline in pancreas transplantation, facilitated pancreas allocation (FPA) was modified August 16, 2016 from an opt-in system for…2019 American Transplant Congress
Pancreata From Donors With Renal Insufficiency: Viable For Transplant?
*Purpose: Pancreata are declined for transplantation for a multitude of reasons. Some of those reasons are organ edema as well as the potential for ischemic…2019 American Transplant Congress
Outcomes after Simultaneous Kidney Pancreas versus Pancreas after Kidney Transplantation
University of Wisconsin, Madison, WI
*Purpose: Simultaneous pancreas and kidney (SPK) or pancreas after kidney (PAK) transplant are potential options for diabetic ESRD patients. Historically, PAK pancreas graft outcomes were…2019 American Transplant Congress
Insulin Treatment in Pancreas Donors on the Intensive Care is a Marker of Beta Cell Death as Evidenced by microRNA Data
University of Manchester, Manchester, United Kingdom
*Purpose: We showed in prior studies that donor insulin use on intensive care predicts early beta cell dysfunction in islet and solid pancreas transplantation. We…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 10
- Next Page »